Por favor, use este identificador para citar o enlazar este ítem: https://doi.org/10.14670/HH-18-657

Título: miR-638 suppresses cervical cancer progression by inhibiting NCAPG2 under the treatment of Tetrandrine
Fecha de publicación: 2024
Editorial: Universidad de Murcia, Departamento de Biologia Celular e Histiologia
Cita bibliográfica: Histology and Histopathology Vol. 39, nº4 (2024)
ISSN: 0213-3911
1699-5848
Materias relacionadas: CDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología
Palabras clave: miR-638
NCAPG2
Tetrandrine
Cervical cancer
Resumen: Background. The interaction of microRNA with Chinese herbal medicines is a promising therapeutic approach for prevention of cervical cancer. Methods. Western blotting or qRT-PCR were carried out to identify the expression of NCAPG2 and miR-638. A tetrandrine (TET) cell model was used to explore the effects of miR-638 and its target gene NCAPG2 using CCK-8, transwell, wound healing, and western blot assays. Furthermore, luciferase activity assay was conducted to measure the interaction among TET, NCAPG2 and miR-638. Results. Under TET treatment, Hela and SiHa cells exhibited repressed cell viability, migration, invasion, and epithelial-mesenchymal transition (EMT), and these effects were further enhanced by high expression of miR-638. In contrast, NCAPG2 expression was low in TET-treated cells and had an opposite effect to that of miR-638. Conclusion. We highlighted that miR-638 suppresses cervical cancer progression by inhibiting NCAPG2 under tetrandrine treatment
Autor/es principal/es: Wang, Min
Liu, Kai
Zhou, Zhongming
Geng, Huizhuan
URI: http://hdl.handle.net/10201/140670
DOI: https://doi.org/10.14670/HH-18-657
Tipo de documento: info:eu-repo/semantics/article
Número páginas / Extensión: 13
Derechos: info:eu-repo/semantics/openAccess
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Aparece en las colecciones:Vol.39, nº4 (2024)

Ficheros en este ítem:
Fichero Descripción TamañoFormato 
Wang-39-497-509-2024 (1).pdf8,78 MBAdobe PDFVista previa
Visualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons